

# The Role of the Androgen Receptor in Triple-Negative B

Women's Health

9, 351-360

DOI: [10.2217/whe.13.33](https://doi.org/10.2217/whe.13.33)

Citation Report

#	ARTICLE	IF	CITATIONS
1	L1CAM is expressed in triple-negative breast cancers and is inversely correlated with Androgen receptor. <i>BMC Cancer</i> , 2014, 14, 958.	1.1	38
2	Breast Cancer Disparities. <i>Surgical Oncology Clinics of North America</i> , 2014, 23, 579-592.	0.6	50
3	Targeting Nuclear Receptors with Marine Natural Products. <i>Marine Drugs</i> , 2014, 12, 601-635.	2.2	17
4	miRNAs and Other Epigenetic Changes as Biomarkers in Triple Negative Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2015, 16, 28347-28376.	1.8	56
5	Heterogeneity of triple-negative breast cancer: mammographic, US, and MR imaging features according to androgen receptor expression. <i>European Radiology</i> , 2015, 25, 419-427.	2.3	23
6	Characterizing Breast Cancer in a Population with Increased Prevalence of Triple-Negative Breast Cancer: Androgen Receptor and ALDH1 Expression in Ghanaian Women. <i>Annals of Surgical Oncology</i> , 2015, 22, 3831-3835.	0.7	27
7	Disparities in Breast Cancer and African Ancestry: A Global Perspective. <i>Breast Journal</i> , 2015, 21, 133-139.	0.4	52
8	Claudin 4 expression in triple-negative breast cancer: correlation with androgen receptors and Ki-67 expression. <i>Annals of Diagnostic Pathology</i> , 2015, 19, 37-42.	0.6	30
9	Activity of ABCG2 Is Regulated by Its Expression and Localization in DHT and Cyclopamine-reated Breast Cancer Cells. <i>Journal of Cellular Biochemistry</i> , 2016, 117, 2249-2259.	1.2	6
10	Comparative Profiling of Triple-Negative Breast Carcinomas Tissue Glycoproteome by Sequential Purification of Glycoproteins and Stable Isotope Labeling. <i>Cellular Physiology and Biochemistry</i> , 2016, 38, 110-121.	1.1	14
11	Triple-Negative/Basal-Like Breast Carcinomas. , 2016, , 431-443.		0
12	Novel targets for paclitaxel nano formulations: Hopes and hypes in triple negative breast cancer. <i>Pharmacological Research</i> , 2016, 111, 577-591.	3.1	46
14	Preclinical evaluation of the AR inhibitor enzalutamide in triple-negative breast cancer cells. <i>Endocrine-Related Cancer</i> , 2016, 23, 323-334.	1.6	50
15	Androgen receptor expression as a prognostic and predictive marker in triple-negative breast cancer patients. <i>Alexandria Journal of Medicine</i> , 2016, 52, 131-140.	0.4	8
16	Androgen Receptor Expression in an Indian Breast Cancer Cohort with Relation to Molecular Subtypes and Response to Neoadjuvant Chemotherapy - a Prospective Clinical Study. <i>Breast Care</i> , 2017, 12, 160-164.	0.8	15
17	Androgen receptor: A promising therapeutic target in breast cancer. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2019, 56, 200-223.	2.7	23
18	Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms. <i>Journal of Hematology and Oncology</i> , 2019, 12, 38.	6.9	66
19	Photodynamic Activity of Vitamin-Chlorin Conjugates at Nanomolar Concentrations against Triple-Negative Breast Cancer Cells. <i>ACS Omega</i> , 2019, 4, 2907-2920.	1.6	9

#	ARTICLE	IF	CITATIONS
20	Clinical Implications of Androgen-Positive Triple-Negative Breast Cancer. <i>Cancers</i> , 2021, 13, 1642.	1.7	21
21	Carcinogenesis of Triple-Negative Breast Cancer and Sex Steroid Hormones. <i>Cancers</i> , 2021, 13, 2588.	1.7	11
22	The importance of androgen receptors in breast cancer. <i>Medicine and Pharmacy Reports</i> , 2021, 94, 273-281.	0.2	2
23	Apocrine Breast Cancer: Unique Features of a Predominantly Triple-Negative Breast Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 5610-5616.	0.7	16
24	Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis. <i>PLoS Medicine</i> , 2016, 13, e1002193.	3.9	75
25	Androgen receptor expression predicts different clinical outcomes for breast cancer patients stratified by hormone receptor status. <i>Oncotarget</i> , 0, 7, 41285-41293.	0.8	47
26	Expression of androgen receptor in invasive ductal breast carcinomas: a clinicopathological study from Jordan. <i>Annals of Saudi Medicine</i> , 2018, 38, 326-335.	0.5	2
27	Triple Negative Breast Cancer: Molecular Classification, Prognostic Markers and Targeted Therapies. <i>Razavi International Journal of Medicine</i> , 2015, 3, .	0.1	2
28	Molecular Targets and Promising Therapeutics of Triple-Negative Breast Cancer. <i>Pharmaceuticals</i> , 2021, 14, 1008.	1.7	9
30	Triple Negative Breast Cancer: Molecular Classification, Prognostic Markers and Targeted Therapies. <i>Razavi International Journal of Medicine</i> , 2015, 3, .	0.1	0
31	Genomic Markers in ER-Negative Breast Cancer. , 2016, , 283-298.		0
32	A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC). <i>Clinical Breast Cancer</i> , 2022, 22, 269-278.	1.1	6
33	Androgen receptor: A new player in triple negative breast cancer management. <i>Journal of Current Oncology</i> , 2020, 3, 51.	0.2	1
34	Triple negative breast cancer: features of clinical course depending on status of androgen receptors and level of its expression. <i>Medical Alphabet</i> , 2020, , 34-37.	0.0	0
35	Androgen receptor (AR) expression in 400 breast carcinomas: is routine AR assessment justified?. <i>American Journal of Cancer Research</i> , 2014, 4, 353-68.	1.4	48
36	Hormonal Homologies between Canine Mammary Cancer and Human Breast Cancer in a Series of Cases. <i>Veterinary Sciences</i> , 2022, 9, 395.	0.6	2
37	HC-1119, a deuterated Enzalutamide, inhibits Migration, Invasion and Metastasis of the AR-positive triple-negative breast Cancer cells. <i>Molecular Biology Reports</i> , 2022, 49, 9231-9240.	1.0	3
38	Triple-Negative/Basal-Like Breast Carcinomas. , 2022, , 445-462.		0

#	ARTICLE	IF	CITATIONS
39	Newly Developed Targeted Therapies Against the Androgen Receptor in Triple-Negative Breast Cancer: A Review. <i>Pharmacological Reviews</i> , 2023, 75, 309-327.	7.1	16
40	Anti-Androgenic Therapies Targeting the Luminal Androgen Receptor of a Typical Triple-Negative Breast Cancer. <i>Cancers</i> , 2023, 15, 233.	1.7	4